<DOC>
	<DOCNO>NCT00545779</DOCNO>
	<brief_summary>This single arm study ass participant preference monthly Bonviva , versus daily weekly alendronate risedronate , treatment postmenopausal osteoporosis . Participants currently daily weekly regimen bisphosphonate therapy ( alendronate risedronate ) answer questionnaire identify participant may benefit monthly Bonviva regimen . Eligible participant discontinue present bisphosphonate treatment , switch monthly Bonviva 150mg per oral ( po ) . At begin end Bonviva treatment , participant complete Osteoporosis Patient Satisfaction Questionnaire . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>BONCURE Study : A Study Monthly Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis Bisphosphonate Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>postmenopausal woman ; &gt; =3 month daily weekly alendronate risedronate treatment prevention postmenopausal osteoporosis . inability stand sit upright position least 60 minute ; hypersensitivity bisphosphonates ; treatment drug affect bone metabolism ; abnormality oesophagus , delay oesophageal emptying .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>